

# Pompe Disease Market Size in the 7MM to Reach USD 2,240.4 Million by 2035 - Epidemiology Report by IMARC Group

*The report also provides a detailed analysis of the current Pompe disease marketed drugs and late-stage pipeline drugs.*


BROOKLYN, NY, UNITED STATES, July 2, 2025 /EINPresswire.com/ -- The [Pompe disease market size reached a value of USD 1,336.1 Million](#) in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 2,240.4 Million by 2035, exhibiting a growth rate (CAGR) of 4.81% during 2025-2035.

The Pompe disease market is centered around the diagnosis and treatment of a rare genetic disorder known as glycogen storage disease type II. The disorder results in toxic accumulation of glycogen in organs and muscles as a result of acid alpha-glucosidase (GAA) enzyme deficiency. The market comprises enzyme replacement therapies (ERT), novel gene therapies, supportive care, diagnostic screening, and patient services.

## Market Growth Outlook

Enzyme replacement therapy is still the mainstay of management. Standard formulations Myozyme and Lumizyme continue to manage infantile- and late-onset presentations, but second-generation agents such as Nexviazyme (avalglucosidase alfa) and Pombiliti (cipaglucosidase alfa) provide enhanced efficacy, greater tissue targeting, and diminished immune response. Combination regimes pairing ERT with stabilizers—like cipaglucosidase and miglustat—are providing better results in late-onset patients.

Gene therapies and substrate reduction strategies are on the move. Pipeline products from such firms as Amicus and Sanofi are moving through early studies. Incentives from regulators—such as orphan designations and fast-track routes—are moving them forward quickly. Diagnostics and



screening are growing as well. With increasing newborn and genetic screening programs around the world, increasing numbers of cases are detected early, allowing for timely treatment initiation. Telemedicine and multidisciplinary care teams are arising to assist patients and families outside of infusion centers.

Request to get a PDF Sample Report: <https://www.imarcgroup.com/pompe-disease-market/requestsampl>

The report also provides a detailed analysis of the current Pompe disease marketed drugs and late-stage pipeline drugs.

## In-Market Drugs

- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance

## Late-Stage Pipeline Drugs

- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance

## Competitive Landscape

The competitive landscape of the Pompe disease market has been studied in the report with the detailed profiles of the key players operating in the market.

- Sanofi
- Aro Biotherapeutics
- Hansa Biopharma
- Denali Therapeutics Inc

Buy the full Pompe Disease Market Epidemiology Report:  
<https://www.imarcgroup.com/checkout?id=29175&method=809>

## 7 Major Countries Covered

- United States

Germany  
France  
United Kingdom  
Italy  
Spain  
Japan

IMARC Group Offers Other Reports:

[Dyssomnias Market Report, Epidemiology Industry Trends](#), Share, Size, Growth, Opportunity, and Forecast

[Minimal Residual Disease Market Report: Epidemiology](#), Industry Trends, Share, Size, Growth, Opportunity, and Forecast

Elena Anderson  
IMARC Services Private Limited  
+1 631-791-1145  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/827655239>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.